New research reveals that patients who stop using popular GLP-1 drugs like Wegovy and Mounjaro may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Findings released in a prominent medical journal points out that while obese individuals frequently drop a large proportion of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals using these drugs must be cognizant of the danger of quick weight regain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to starting weight within about one and a half years.
Analyzing Treatments
The analysis, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with conventional dieting.
Scientists emphasize that individuals who shed pounds through diet and exercise generally have a more gradual creep back—around 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Nutrition scientists suggest the way of the jabs is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making excessive eating much more probable."
A Lifelong Disease?
Health authorities suggest the jabs for individuals with weight-linked health risks, alongside recommended lifestyle changes.
A number of clinicians contend that, given the likelihood of weight regain, the therapy might need to be life-long.
This perspective is supported by pharmaceutical companies, who say that the results "highlight the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
Patient Accounts
People who have discontinued the medication describe a intense return of cravings.
"It felt as if a switch flipping and you're instantly starving," described an individual.
The struggle is worsened if users have not adopted permanent dietary or behavioural modifications during therapy.
Growing Interest
Figures indicate that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
Finally, researchers caution that while the jabs are potent agents for shedding pounds, they are not a standalone fix and lasting health benefits likely depends on integrated behavioural management.
